Recent Research Analysts’ Ratings Changes for Certara (CERT)

Several brokerages have updated their recommendations and price targets on shares of Certara (NASDAQ: CERT) in the last few weeks:

• 12/8/2025 – Certara had its “sell (d+)” rating reaffirmed by analysts at Weiss Ratings.
• 12/1/2025 – Certara had its “sell (d+)” rating reaffirmed by analysts at Weiss Ratings.
• 11/25/2025 – Certara had its “sell (d+)” rating reaffirmed by analysts at Weiss Ratings.
• 11/24/2025 – Certara was upgraded by analysts at Wall Street Zen from a “hold” rating to a “buy” rating.
• 11/21/2025 – Certara was given a new $10.00 price target on by analysts at Redburn Partners.
• 11/21/2025 – Certara was upgraded by analysts at Rothschild Redb to a “strong-buy” rating.
• 11/21/2025 – Certara is now covered by analysts at Rothschild & Co Redburn. They set a “buy” rating and a $10.00 price target on the stock.
• 11/19/2025 – Certara had its “sell (d+)” rating reaffirmed by analysts at Weiss Ratings.
• 11/16/2025 – Certara was downgraded by analysts at Wall Street Zen from a “buy” rating to a “hold” rating.
• 11/13/2025 – Certara had its “sell (d+)” rating reaffirmed by analysts at Weiss Ratings.
• 11/13/2025 – Certara is now covered by analysts at BMO Capital Markets. They set a “market perform” rating and a $9.00 price target on the stock.
• 11/8/2025 – Certara was upgraded by analysts at Wall Street Zen from a “hold” rating to a “buy” rating.
• 11/7/2025 – Certara had its price target lowered by analysts at Barclays PLC from $16.00 to $14.00. They now have an “overweight” rating on the stock.

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.